Global Antihemophilic Factor (Recombinant) Market Growth (Status and Outlook) 2022-2028
- LP 4891030
- 85 Pages
- March 2022
- Pharmaceuticals
The United States Antihemophilic Factor (Recombinant) market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Antihemophilic Factor (Recombinant) market, reaching US$ million by the year 2028. As for the Europe Antihemophilic Factor (Recombinant) landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Antihemophilic Factor (Recombinant) players cover Takeda, Bayer, CSL, and Pfizer, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Antihemophilic Factor (Recombinant) market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
250IU
500IU
1000IU
1500IU
2000IU
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Clinic
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Takeda
Bayer
CSL
Pfizer
Biogen
Octapharma
NovoNordisk
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antihemophilic Factor (Recombinant) Market Size 2017-2028
2.1.2 Antihemophilic Factor (Recombinant) Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Antihemophilic Factor (Recombinant) Segment by Type
2.2.1 250IU
2.2.2 500IU
2.2.3 1000IU
2.2.4 1500IU
2.2.5 2000IU
2.3 Antihemophilic Factor (Recombinant) Market Size by Type
2.3.1 Antihemophilic Factor (Recombinant) Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
2.4 Antihemophilic Factor (Recombinant) Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Antihemophilic Factor (Recombinant) Market Size by Application
2.5.1 Antihemophilic Factor (Recombinant) Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
3 Antihemophilic Factor (Recombinant) Market Size by Player
3.1 Antihemophilic Factor (Recombinant) Market Size Market Share by Players
3.1.1 Global Antihemophilic Factor (Recombinant) Revenue by Players (2020-2022)
3.1.2 Global Antihemophilic Factor (Recombinant) Revenue Market Share by Players (2020-2022)
3.2 Global Antihemophilic Factor (Recombinant) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Antihemophilic Factor (Recombinant) by Regions
4.1 Antihemophilic Factor (Recombinant) Market Size by Regions (2017-2022)
4.2 Americas Antihemophilic Factor (Recombinant) Market Size Growth (2017-2022)
4.3 APAC Antihemophilic Factor (Recombinant) Market Size Growth (2017-2022)
4.4 Europe Antihemophilic Factor (Recombinant) Market Size Growth (2017-2022)
4.5 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Growth (2017-2022)
5 Americas
5.1 Americas Antihemophilic Factor (Recombinant) Market Size by Country (2017-2022)
5.2 Americas Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022)
5.3 Americas Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antihemophilic Factor (Recombinant) Market Size by Region (2017-2022)
6.2 APAC Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022)
6.3 APAC Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Antihemophilic Factor (Recombinant) by Country (2017-2022)
7.2 Europe Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022)
7.3 Europe Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antihemophilic Factor (Recombinant) by Region (2017-2022)
8.2 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022)
8.3 Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Antihemophilic Factor (Recombinant) Market Forecast
10.1 Global Antihemophilic Factor (Recombinant) Forecast by Regions (2023-2028)
10.1.1 Global Antihemophilic Factor (Recombinant) Forecast by Regions (2023-2028)
10.1.2 Americas Antihemophilic Factor (Recombinant) Forecast
10.1.3 APAC Antihemophilic Factor (Recombinant) Forecast
10.1.4 Europe Antihemophilic Factor (Recombinant) Forecast
10.1.5 Middle East & Africa Antihemophilic Factor (Recombinant) Forecast
10.2 Americas Antihemophilic Factor (Recombinant) Forecast by Country (2023-2028)
10.2.1 United States Antihemophilic Factor (Recombinant) Market Forecast
10.2.2 Canada Antihemophilic Factor (Recombinant) Market Forecast
10.2.3 Mexico Antihemophilic Factor (Recombinant) Market Forecast
10.2.4 Brazil Antihemophilic Factor (Recombinant) Market Forecast
10.3 APAC Antihemophilic Factor (Recombinant) Forecast by Region (2023-2028)
10.3.1 China Antihemophilic Factor (Recombinant) Market Forecast
10.3.2 Japan Antihemophilic Factor (Recombinant) Market Forecast
10.3.3 Korea Antihemophilic Factor (Recombinant) Market Forecast
10.3.4 Southeast Asia Antihemophilic Factor (Recombinant) Market Forecast
10.3.5 India Antihemophilic Factor (Recombinant) Market Forecast
10.3.6 Australia Antihemophilic Factor (Recombinant) Market Forecast
10.4 Europe Antihemophilic Factor (Recombinant) Forecast by Country (2023-2028)
10.4.1 Germany Antihemophilic Factor (Recombinant) Market Forecast
10.4.2 France Antihemophilic Factor (Recombinant) Market Forecast
10.4.3 UK Antihemophilic Factor (Recombinant) Market Forecast
10.4.4 Italy Antihemophilic Factor (Recombinant) Market Forecast
10.4.5 Russia Antihemophilic Factor (Recombinant) Market Forecast
10.5 Middle East & Africa Antihemophilic Factor (Recombinant) Forecast by Region (2023-2028)
10.5.1 Egypt Antihemophilic Factor (Recombinant) Market Forecast
10.5.2 South Africa Antihemophilic Factor (Recombinant) Market Forecast
10.5.3 Israel Antihemophilic Factor (Recombinant) Market Forecast
10.5.4 Turkey Antihemophilic Factor (Recombinant) Market Forecast
10.5.5 GCC Countries Antihemophilic Factor (Recombinant) Market Forecast
10.6 Global Antihemophilic Factor (Recombinant) Forecast by Type (2023-2028)
10.7 Global Antihemophilic Factor (Recombinant) Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Takeda
11.1.1 Takeda Company Information
11.1.2 Takeda Antihemophilic Factor (Recombinant) Product Offered
11.1.3 Takeda Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Takeda Main Business Overview
11.1.5 Takeda Latest Developments
11.2 Bayer
11.2.1 Bayer Company Information
11.2.2 Bayer Antihemophilic Factor (Recombinant) Product Offered
11.2.3 Bayer Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Bayer Main Business Overview
11.2.5 Bayer Latest Developments
11.3 CSL
11.3.1 CSL Company Information
11.3.2 CSL Antihemophilic Factor (Recombinant) Product Offered
11.3.3 CSL Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 CSL Main Business Overview
11.3.5 CSL Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Antihemophilic Factor (Recombinant) Product Offered
11.4.3 Pfizer Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Biogen
11.5.1 Biogen Company Information
11.5.2 Biogen Antihemophilic Factor (Recombinant) Product Offered
11.5.3 Biogen Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Biogen Main Business Overview
11.5.5 Biogen Latest Developments
11.6 Octapharma
11.6.1 Octapharma Company Information
11.6.2 Octapharma Antihemophilic Factor (Recombinant) Product Offered
11.6.3 Octapharma Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 Octapharma Main Business Overview
11.6.5 Octapharma Latest Developments
11.7 NovoNordisk
11.7.1 NovoNordisk Company Information
11.7.2 NovoNordisk Antihemophilic Factor (Recombinant) Product Offered
11.7.3 NovoNordisk Antihemophilic Factor (Recombinant) Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 NovoNordisk Main Business Overview
11.7.5 NovoNordisk Latest Developments
12 Research Findings and Conclusion
Table 1. Antihemophilic Factor (Recombinant) Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of 250IU
Table 3. Major Players of 500IU
Table 4. Major Players of 1000IU
Table 5. Major Players of 1500IU
Table 6. Major Players of 2000IU
Table 7. Antihemophilic Factor (Recombinant) Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022) & ($ Millions)
Table 9. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
Table 10. Antihemophilic Factor (Recombinant) Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 11. Global Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022) & ($ Millions)
Table 12. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
Table 13. Global Antihemophilic Factor (Recombinant) Revenue by Players (2020-2022) & ($ Millions)
Table 14. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Player (2020-2022)
Table 15. Antihemophilic Factor (Recombinant) Key Players Head office and Products Offered
Table 16. Antihemophilic Factor (Recombinant) Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Antihemophilic Factor (Recombinant) Market Size by Regions 2017-2022 & ($ Millions)
Table 20. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Regions (2017-2022)
Table 21. Americas Antihemophilic Factor (Recombinant) Market Size by Country (2017-2022) & ($ Millions)
Table 22. Americas Antihemophilic Factor (Recombinant) Market Size Market Share by Country (2017-2022)
Table 23. Americas Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022) & ($ Millions)
Table 24. Americas Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
Table 25. Americas Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022) & ($ Millions)
Table 26. Americas Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
Table 27. APAC Antihemophilic Factor (Recombinant) Market Size by Region (2017-2022) & ($ Millions)
Table 28. APAC Antihemophilic Factor (Recombinant) Market Size Market Share by Region (2017-2022)
Table 29. APAC Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022) & ($ Millions)
Table 30. APAC Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
Table 31. APAC Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022) & ($ Millions)
Table 32. APAC Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
Table 33. Europe Antihemophilic Factor (Recombinant) Market Size by Country (2017-2022) & ($ Millions)
Table 34. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Country (2017-2022)
Table 35. Europe Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022) & ($ Millions)
Table 36. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
Table 37. Europe Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022) & ($ Millions)
Table 38. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
Table 39. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Region (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Region (2017-2022)
Table 41. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Type (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Type (2017-2022)
Table 43. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size by Application (2017-2022) & ($ Millions)
Table 44. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Application (2017-2022)
Table 45. Key Market Drivers & Growth Opportunities of Antihemophilic Factor (Recombinant)
Table 46. Key Market Challenges & Risks of Antihemophilic Factor (Recombinant)
Table 47. Key Industry Trends of Antihemophilic Factor (Recombinant)
Table 48. Global Antihemophilic Factor (Recombinant) Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 49. Global Antihemophilic Factor (Recombinant) Market Size Market Share Forecast by Regions (2023-2028)
Table 50. Global Antihemophilic Factor (Recombinant) Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 51. Global Antihemophilic Factor (Recombinant) Market Size Market Share Forecast by Type (2023-2028)
Table 52. Global Antihemophilic Factor (Recombinant) Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 53. Global Antihemophilic Factor (Recombinant) Market Size Market Share Forecast by Application (2023-2028)
Table 54. Takeda Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 55. Takeda Antihemophilic Factor (Recombinant) Product Offered
Table 56. Takeda Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 57. Takeda Main Business
Table 58. Takeda Latest Developments
Table 59. Bayer Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 60. Bayer Antihemophilic Factor (Recombinant) Product Offered
Table 61. Bayer Main Business
Table 62. Bayer Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 63. Bayer Latest Developments
Table 64. CSL Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 65. CSL Antihemophilic Factor (Recombinant) Product Offered
Table 66. CSL Main Business
Table 67. CSL Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 68. CSL Latest Developments
Table 69. Pfizer Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 70. Pfizer Antihemophilic Factor (Recombinant) Product Offered
Table 71. Pfizer Main Business
Table 72. Pfizer Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 73. Pfizer Latest Developments
Table 74. Biogen Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 75. Biogen Antihemophilic Factor (Recombinant) Product Offered
Table 76. Biogen Main Business
Table 77. Biogen Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 78. Biogen Latest Developments
Table 79. Octapharma Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 80. Octapharma Antihemophilic Factor (Recombinant) Product Offered
Table 81. Octapharma Main Business
Table 82. Octapharma Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 83. Octapharma Latest Developments
Table 84. NovoNordisk Details, Company Type, Antihemophilic Factor (Recombinant) Area Served and Its Competitors
Table 85. NovoNordisk Antihemophilic Factor (Recombinant) Product Offered
Table 86. NovoNordisk Main Business
Table 87. NovoNordisk Antihemophilic Factor (Recombinant) Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 88. NovoNordisk Latest Developments
List of Figures
Figure 1. Antihemophilic Factor (Recombinant) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antihemophilic Factor (Recombinant) Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Type in 2021
Figure 7. Antihemophilic Factor (Recombinant) in Hospital
Figure 8. Global Antihemophilic Factor (Recombinant) Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Antihemophilic Factor (Recombinant) in Clinic
Figure 10. Global Antihemophilic Factor (Recombinant) Market: Clinic (2017-2022) & ($ Millions)
Figure 11. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Application in 2021
Figure 12. Global Antihemophilic Factor (Recombinant) Revenue Market Share by Player in 2021
Figure 13. Global Antihemophilic Factor (Recombinant) Market Size Market Share by Regions (2017-2022)
Figure 14. Americas Antihemophilic Factor (Recombinant) Market Size 2017-2022 ($ Millions)
Figure 15. APAC Antihemophilic Factor (Recombinant) Market Size 2017-2022 ($ Millions)
Figure 16. Europe Antihemophilic Factor (Recombinant) Market Size 2017-2022 ($ Millions)
Figure 17. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size 2017-2022 ($ Millions)
Figure 18. Americas Antihemophilic Factor (Recombinant) Value Market Share by Country in 2021
Figure 19. Americas Antihemophilic Factor (Recombinant) Consumption Market Share by Type in 2021
Figure 20. Americas Antihemophilic Factor (Recombinant) Market Size Market Share by Application in 2021
Figure 21. United States Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 22. Canada Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 23. Mexico Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 24. Brazil Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 25. APAC Antihemophilic Factor (Recombinant) Market Size Market Share by Region in 2021
Figure 26. APAC Antihemophilic Factor (Recombinant) Market Size Market Share by Application in 2021
Figure 27. China Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 28. Japan Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 29. Korea Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 30. Southeast Asia Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 31. India Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 32. Australia Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 33. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Country in 2021
Figure 34. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Type in 2021
Figure 35. Europe Antihemophilic Factor (Recombinant) Market Size Market Share by Application in 2021
Figure 36. Germany Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 37. France Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 38. UK Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 39. Italy Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 40. Russia Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 41. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Region in 2021
Figure 42. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Type in 2021
Figure 43. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size Market Share by Application in 2021
Figure 44. Egypt Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 45. South Africa Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 46. Israel Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 47. Turkey Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 48. GCC Country Antihemophilic Factor (Recombinant) Market Size Growth 2017-2022 ($ Millions)
Figure 49. Americas Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 50. APAC Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 51. Europe Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 52. Middle East & Africa Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 53. United States Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 54. Canada Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 55. Mexico Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 56. Brazil Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 57. China Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 58. Japan Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 59. Korea Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 60. Southeast Asia Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 61. India Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 62. Australia Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 63. Germany Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 64. France Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 65. UK Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 66. Italy Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 67. Russia Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 68. Spain Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 69. Egypt Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 70. South Africa Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 71. Israel Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 72. Turkey Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Figure 73. GCC Countries Antihemophilic Factor (Recombinant) Market Size 2023-2028 ($ Millions)
Similar Reports
The United States pneumococcal & meningococcal vaccines market is set to surpass US$ 7.5 Million by the year end of 2025. “United States Pneumococcal & Meningococcal Vaccines Market by Company Profile, Deals Type, Brand Analysis, Share, Key Trends & Opportunities to 2025” presents an in–depth assessment of the United States pneumococcal & meningococcal vaccines market dynamics, opportunitie...
- Publish Date: June 24, 2019
- $1050
The global human immunodeficiency virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025. “Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 – 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts” presents an in-depth assessment of the global human immunodeficiency virus (HIV) drugs market dynamics, opportunities, future roadmap, competitive landscap...
- Publish Date: February 18, 2019
- $1290
The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘’Global Blockbuster Drugs Market 2015 - 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the m...
- Publish Date: December 11, 2018
- $1390
